Cargando…
A Smo/Gli Multitarget Hedgehog Pathway Inhibitor Impairs Tumor Growth
Pharmacological Hedgehog (Hh) pathway inhibition has emerged as a valuable anticancer strategy. A number of small molecules able to block the pathway at the upstream receptor Smoothened (Smo) or the downstream effector glioma-associated oncogene 1 (Gli1) has been designed and developed. In a recent...
Autores principales: | Lospinoso Severini, Ludovica, Quaglio, Deborah, Basili, Irene, Ghirga, Francesca, Bufalieri, Francesca, Caimano, Miriam, Balducci, Silvia, Moretti, Marta, Romeo, Isabella, Loricchio, Elena, Maroder, Marella, Botta, Bruno, Mori, Mattia, Infante, Paola, Di Marcotullio, Lucia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826940/ https://www.ncbi.nlm.nih.gov/pubmed/31601026 http://dx.doi.org/10.3390/cancers11101518 |
Ejemplares similares
-
DUBs Activating the Hedgehog Signaling Pathway: A Promising Therapeutic Target in Cancer
por: Bufalieri, Francesca, et al.
Publicado: (2020) -
Drug Delivery Systems for Hedgehog Inhibitors in the Treatment of SHH-Medulloblastoma
por: Caimano, Miriam, et al.
Publicado: (2021) -
Targeting Hedgehog Signalling through the Ubiquitylation Process: The Multiple Roles of the HECT-E3 Ligase Itch
por: Infante, Paola, et al.
Publicado: (2019) -
The RNA-Binding Ubiquitin Ligase MEX3A Affects Glioblastoma Tumorigenesis by Inducing Ubiquitylation and Degradation of RIG-I
por: Bufalieri, Francesca, et al.
Publicado: (2020) -
Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?
por: Lospinoso Severini, Ludovica, et al.
Publicado: (2022)